Pharmaceutical manufacturers of Cycloserine

Solara is an API manufacturer focused on research and customer satisfaction, operating in over 75 countries. They specialize in producing APIs for niche therapeutic categories, including complex products like polymer-based APIs and injectable APIs. The company has a team of experienced scientists supported by 6 manufacturing facilities and 2 R&D centers. Additionally, Solara offers Contract Research and Manufacturing Services (CRAMS) from discovery to late phase commercial manufacturing. Solara Active Pharma Sciences, with roots in Strides Shasun Ltd. and Sequent Scientific Ltd., is committed to providing value-based products while prioritizing customer needs. The company has 140+ scientists working at 2 R&D centers and 4 API manufacturing facilities, all with global approvals and 2 dedicated R&D facilities.

Established in 1876 by Colonel Eli Lilly, Lilly has been dedicated to producing high-quality medications that address genuine needs in a time when unreliable potions were sold by dubious individuals. His encouragement to future generations of staff has been to continuously improve upon what they find. Over 140 years later, we remain steadfast in upholding his vision across all aspects of our operations and the individuals we cater to, beginning with those who use our medications and extending to healthcare professionals, employees, and the communities where we are situated.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

SCL was incorporated on December 20, 1993, as a Private Limited Company. Initially, it manufactured intermediates. On July 1, 1997, the company became a Public Limited Company and adopted its current name. In 2004, SCL established a new API manufacturing facility. Today, it offers a wide range of APIs and advanced intermediates in various therapeutic segments such as NSAIDs, cardiology, anti-cholinergic, CNS, anti-filarials, and anthelmintics, among others, to its customers. We are based in Panchkula, near Chandigarh, with two manufacturing facilities in Derabassi, Mohali (Punjab), for intermediates and APIs. The marketing office is located in Delhi NCR. We have acquired 22 acres of land for expanding facilities near the current site.

Dong-A has held the position of the largest pharmaceutical company in Korea since 1967. Our predominant market presence is attributed to internally developed products such as Suganon tab, Evogliptin, which is a DPP-4 inhibitor for type 2 diabetes mellitus, Zydena tab, which is Udenafil, the fourth PDE5 inhibitor globally for erectile dysfunction, Stillen tab, a herbal treatment for gastritis with Eupatilin, and Motilitone tab, which contains Corydaline for functional dyspepsia. Additionally, we provide branded generic drugs (anti-cancer, anti-TB, etc.), bio-pharmaceutical, IMD, APIs, and OTC products.

ST Pharm has provided exceptional custom production services for oligonucleotides and small molecule APIs CDMO to fulfill clients’ elevated requirements in pharmaceutical development while adhering to cGMP regulations. The enhancement of oligonucleotide manufacturing capabilities has emerged as a new driving force for the future of the pharmaceutical industry

SPC Research Institute of Food and BioTechnologyBusiness Integrity, SPC WAY encompasses the principles established by SPC to achieve its centennial as a worldwide enterprise. These principles are rooted in the Sangmidang Spirit and serve as the fundamental philosophy and compass for all SPC members. The Management Philosophy is the driving force behind SPC's existence. Through setting innovative challenges, SPC Group endeavors to delight customers with high-quality, nutritious, and delicious products.